Hematologic Malignancy
Secondary Myelodysplastic Syndrome
CI-CAN-00001492Explore in graph →
Hematologic8 active trials
- NCIt
- C27280
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001492Explore in graph →
Clinical trials
33 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | recruiting | Phase 1 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies(Orca-T) | active not recruiting | Phase 3 | 187 | Orca Biosystems, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | completed | Phase 1 | 21 | Brian JonasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT01168219 | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02485535 | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | completed | Phase 1 | 12 | University of ChicagoOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00313586 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 2 | 197 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01132586 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials